SCHEMBL5479249

SCHEMBL5479249

CC(CCN(C)Cc1ccccc1)Oc1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TMEM97 Q5BJF2 3/20 0.48
SIGMAR1 Q99720 3/20 0.48
PPARA Q07869 1/20 0.47
MAPT P10636 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ATM Q13315 2/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
MAPK1 P28482 1/20 0.43
CCR5 P51681 1/20 0.42
CARM1 Q86X55 1/20 0.40
PRMT6 Q96LA8 1/20 0.40
PRMT8 Q9NR22 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14565806 1.00 GAA (0.49) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL14565808 0.88 GAA (0.47) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL5474247 0.88 GAA (0.47) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL14565807 0.85 GAA (0.47) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL5470985 0.85 GAA (0.47) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL5477259 0.84 GAA (0.44) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL5477264 0.84 GAA (0.44) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL5479173 0.81 GAA (0.43) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL5479182 0.81 GAA (0.43) GAASMN1; SMN2TMEM97SIGMAR1PPARA
SCHEMBL14581635 0.79 TMEM97 (0.43) GAASMN1; SMN2TMEM97SIGMAR1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070072859-A1 Pharmaceutical compounds ELI LILLY AND COMPANY (US) 2007-03-29 US disclosed
EP-1725518-A1 PHARMACEUTICAL COMPOUNDS ELI LILLY AND COMPANY (US) 2006-11-29 EP disclosed
WO-2005092835-A1 PHARMACEUTICAL COMPOUNDS ELI LILLY AND COMPANY (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072859-A1 Pharmaceutical compounds ADRB3, HTR3C, SLC6A2 GAA 3273/4885SMN1; SMN2 1292/4885TMEM97 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.